Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Hinova Details Progress of Candidate for AR+ Triple-Negative Breast Cancer

publication date: Jul 8, 2024

Chengdu Hinova Pharma received US FDA Fast Track designation for HP518, an investigational drug for Androgen-receptor positive (AR+) triple-negative breast cancer (TNBC). HP518 is a potent PROTAC AR degrader that has shown efficacy in AR+ TNBC. According to Hinova, the molecular subforms of TNBC are particularly aggressive forms of breast cancer, without targeted treatment options but accounting for approximately 15-20% of all breast cancer cases. They lack estrogen and progesterone receptors along with HER2 expression. However, up to 50% of TNBC cases express the androgen receptor, HP518’s potential target. More details....

Stock Symbol: (SHA: 688302)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital